Science
Researchers develop targeted mRNA delivery system to fight tumors
Wired reports that a new nanoparticle method reprograms tumor immune cells in early testing.
The short version
- A research team led by University of Adelaide professor Chunxia Zhao developed antibody-guided nanoparticles that deliver mRNA and resiquimod directly to tumor-associated macrophages.[Wired]
- In laboratory and mouse models with aggressive breast cancer, the treatment slowed tumor growth and reduced immunosuppressive macrophages by 63 percent.[Wired]
- Combining the nanoparticles with immune checkpoint inhibitors increased beneficial T cells in tumors and lymph nodes, though it did not shrink tumors further.[Wired]
- Researchers emphasized that additional safety testing is required before initiating human clinical trials.[Wired]
Key facts
- The delivery system uses nanoparticles targeted at TREM2 proteins on tumor-associated macrophages to supply CXCL9-encoding mRNA and resiquimod.[Wired]
- Testing in mice with aggressive breast cancer yielded a 63 percent decrease in immunosuppressive macrophages and reduced tumor growth after three doses.[Wired]
- Combining the therapy with immune checkpoint inhibitors boosted T-cell counts in tumors and lymph nodes without providing additional tumor size reduction.[Wired]
What remains uncertain
- It remains unknown whether the treatment will prove safe and effective in human trials, as comprehensive safety evaluations are still pending.[Wired]
Sources
Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.